

Biotechnology Funding, Risk & Valuation

Development phase, Risk & Funding

Raising funding:

- Critical, especially in the early pre-revenue research and development stages including for clinical trials and the regulatory approval lifecycle see development phase table alongside
- Often occurs in stages to meet milestones in the development and regulatory approval processes
- Affected by factors including:
 - Internal entity considerations
 - Board & management
 - IP assets
 - External factors
 - Regulatory & political environment
 - Competitors
 - Economy, stock markets & exchange rates

Risk

- Highest in the research and development stages (including trials), particularly during phase 2 trials success of the product in clinical trials, raising sufficient funding, regulations and FDA approval
- Affected by product pipeline more products could signal less risk/more diversification (depending on stage of development)
- Risk inversely related to cash balance; directly related to funding requirements - below right

Funding types:

- The type of funding secured in the early stages of a venture affects the capital and ownership structure of the entity:
 - Dilutive diminishes ownership
 - Equity for capital angle investors or venture capitalists
 - Share issue to new investors through public or private funding round
 - Non-dilutive
 - R&D tax incentives
 - Foundations (NGOs, NPOs)
 - Industry partnerships
 - Debt
 - Revenue

Development phase features and risk


<u>Development pridse readeres and risk</u>				
	Development phase	Characteristics	Activities	Risk & Investor considerations
	Start-up	 Often based on one promising innovation (technology or platform) 	 Prototyping Entity establishment – legal structures, registration, governance structures IP asset establishment or acquisition i.e. universities 	 Risk: High High level of failure Funding sources: friends/family, seed & angel investors, government grants
	Research & Development	 Product development Clinical and field trials 	 Proof of concept testing & expansion Toxicology studies (<i>in</i> <i>silico</i>, <i>in vitro</i>, animal) Clinical trial start Regulatory requirement focus IP management and strategy Commercial considerations Seek funding (for next phase) 	 Risk: Highest More data available on potential success of the product Distinguish between early & late stage clinical trials - successful phase 2 clinical trials critical Funding sources: angel investors, government grants, venture financing, private equity, partnerships, IPO
	Commercial- isation & Marketing	 Revenue generation Internal exploitation of IP assets - take to market Out licensing or sale of IP assets and/or technology 	 Cash flow – up-front milestone or royalty payments, revenue (dependent on regulatory approval) Reimbursement Approval by other regulatory bodies for international expansion 	 Risk: Variable - depends on market uptake and product success Funding: strategic partners, capital markets
Ā	Continued growth or liquidity event	 Post-launch support and strategic exploitation of IP asset (life of patent portfolio) 	 Use of revenue for accelerated growth and development or in- licensing of new technologies Spin-out or subsidiary company creation for further specialisation in a new technology(ies) 	 Risk: Lower – several assets and/or revenue stream offer diversification



Valuation methods

Biotechs are challenging to value given their unique lifecycle and the nature of their assets, i.e. largely IP/non-tangible assets valuation of which is specialised and complex

Valuation methods used differ to most other sectors, and include:



- Discounted Cash Flow (DCF) based on future positive and negative free cash flow projections
- Market comparable multiples for calculating value based on data from public, peer-group companies; market capitalisation, peer/comparable enterprise values (disease area, stage of development, size (employees)
- Sum of parts total net present value (NPV) of a company; sum of risk-• adjusted NPV (rNPV) of lead product(s) in development and the DCF of all other company operations, takes probability of success/failure into account; rNPV calculation can be split into:
 - Development Phase cost and timeline for bringing product to different markets
 - Market Phase disease prevalence (market size), cure vs prolonged treatment, drug pricing in different markets, competition, development timelines for different markets
 - Risk Adjustment product-specific attrition risk
 - Discounting to Present Value general business risk and cost of capital

Industry nuances summary

- Often unprofitable with no or limited revenue
- High risk high chance of failure i.e. up to ~90% of drugs in development either do not reach the approval stage or are not approved / 5–15% success rate on commercialisation attempts
- Long product development lead times i.e. successful companies often take ~10 to 15 years to achieve commercialisation
- Potential for high reward:
 - For drugs/products which do get approved
 - For early/start-up stage investors if the company is acquired or licensed by a larger entity
- Limited dividends due to limited revenue generation
- DCF models often used to value early-stage biotechnology companies, however success is linked to whether products reach approval and are approved



References and further details

AusBiotech. Guide to Life Sciences Investing. https://www.ausbiotech.org/documents/item/451 (2018).